CN114790472B - 一种果糖糖基化的姜黄素、制备方法及应用 - Google Patents
一种果糖糖基化的姜黄素、制备方法及应用 Download PDFInfo
- Publication number
- CN114790472B CN114790472B CN202210301654.2A CN202210301654A CN114790472B CN 114790472 B CN114790472 B CN 114790472B CN 202210301654 A CN202210301654 A CN 202210301654A CN 114790472 B CN114790472 B CN 114790472B
- Authority
- CN
- China
- Prior art keywords
- curcumin
- glycosylated
- fructosylated
- fructosyl
- levansucrase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 144
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 58
- 229940109262 curcumin Drugs 0.000 title claims abstract description 58
- 239000004148 curcumin Substances 0.000 title claims abstract description 58
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 108010036940 Levansucrase Proteins 0.000 claims abstract description 33
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 15
- 229930006000 Sucrose Natural products 0.000 claims abstract description 15
- 239000005720 sucrose Substances 0.000 claims abstract description 15
- 239000000937 glycosyl acceptor Substances 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 239000000348 glycosyl donor Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- ZTOKUMPYMPKCFX-CZNUEWPDSA-N (E)-17-[(2R,3R,4S,5S,6R)-6-(acetyloxymethyl)-3-[(2S,3R,4S,5S,6R)-6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxyoctadec-9-enoic acid Chemical compound OC(=O)CCCCCCC/C=C/CCCCCCC(C)O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O1 ZTOKUMPYMPKCFX-CZNUEWPDSA-N 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- WXKPPMQZRGORPB-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;acetate Chemical compound [Na+].CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O WXKPPMQZRGORPB-UHFFFAOYSA-M 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000009465 prokaryotic expression Effects 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 abstract description 14
- -1 glucosyl curcumin Chemical compound 0.000 abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000386 donor Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241000577554 Lactobacillus zeae Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000006097 fructosylation Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000006098 transglycosylation Effects 0.000 description 2
- 238000005918 transglycosylation reaction Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101000630755 Arabidopsis thaliana Sucrose synthase 1 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001136168 Clavibacter michiganensis Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- HQRWPYNQQYEQRQ-ORWZVCRDSA-N Curcumin diglucoside Chemical compound C=1C=C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C(OC)=CC=1\C=C\C(\O)=C\C(=O)\C=C\C(C=C1OC)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HQRWPYNQQYEQRQ-ORWZVCRDSA-N 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229910001374 Invar Inorganic materials 0.000 description 1
- 101150046193 LS gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010043934 Sucrose synthase Proteins 0.000 description 1
- 241001149594 Trichoderma deliquescens Species 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 150000003306 rutin derivatives Chemical class 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种果糖糖基化的姜黄素、制备方法及应用,以果聚糖蔗糖酶为催化剂,以姜黄素为糖基受体,以蔗糖作为糖基化供体进行酶促糖基化反应,获得果糖糖基化的姜黄素,溶解度要远高于对应的葡萄糖糖基化的姜黄素,从而拥有更好的生物利用度。
Description
技术领域
本发明涉及糖基化姜黄素,具体为一种果糖糖基化的姜黄素、制备方法及应用。
背景技术
姜黄素类化合物(curcuminoids)是从中药姜黄的根、茎中提取出来的一种酚类色素,主要包括姜黄素(curcumin)、去甲氧基姜黄素(demethoxycurcumin)和去双甲氧基姜黄素(bisdemethoxycurcumin),以姜黄素为主。
姜黄素类化合物是中药姜黄的重要活性成分,其被发现具有姜黄素具有抗癌、抗炎、抗氧化、降血脂及抗动脉粥样硬化、抗抑郁、抗帕金森氏病等多种药理活性,而且无毒,无副作用,应用领域十分广泛。
但是姜黄素水溶性和脂溶性均很差,且结构不稳定,在体内容易被降解,导致其生物利用度低,糖基化衍生被认为是提高姜黄素水溶性和生物利用度的最具有潜力的衍生化方法。
专利申请CN201310356241.5公开了一种利用潮解胶霉(Gliocladiumdeliquescens)NRRL1086菌株细胞催化糖苷化使得姜黄素糖基化的技术方案,其糖基化转化率可达60%,产物为葡萄糖单糖基化的姜黄素化合物。
专利申请CN202110188213.1公开了一种利用蔗糖合成酶AtSUS1和糖基转移酶CaUGT2双酶联合表达方式催化姜黄素糖基化的技术方案,其姜黄素化合能够在21h内被重组菌CaUGT2-AtSUS1基本全部转化,产物为葡萄糖单糖基衍生化的姜黄素化合物,转化率达到98%。
专利申请CN201910160498.0公开了利用玉米乳杆菌(Lactobacillus zeae)CGMCCNo.17026菌体细胞催化姜黄素糖基化的技术方案,其产物为葡萄糖单糖基化衍生以及葡萄糖双糖基化衍生的姜黄素化合物,其中姜黄素葡萄糖苷转化率为39%,姜黄素双葡萄糖苷转化率为4%。
然而,葡萄糖单糖基衍生化的姜黄素,即姜黄素-4’-O-β-D-葡萄糖苷(Curcumin-4’-O-β-D-glucoside,)其溶解性也仅有7.0×10-3μmol/mL。
目前,如何获得生物利用度更高、结构稳定、溶解度更好的姜黄素衍生物,是行业研究的热点和痛点。
发明内容
基于上述情况,我们公开了一种果糖糖基化的姜黄素、制备方法及应用,解决上述技术问题。
本发明结合现有技术中提供一种果糖糖基化的姜黄素、制备方法及应用,以果聚糖蔗糖酶为催化剂,以姜黄素为糖基受体,以蔗糖作为糖基化供体进行酶促糖基化反应,获得果糖糖基化的姜黄素,溶解度要远高于对应的葡萄糖糖基化的姜黄素,从而拥有更好的生物利用度。
果聚糖蔗糖酶(Levansucrases,LSs)(EC 2.4.1.10)属于糖苷酶家族GH68,该酶既具有转糖基活性,同时还具有水解活性。该酶的糖苷水解活性可以将蔗糖水解为葡萄糖和果糖。同时果聚糖蔗糖酶也可以以木糖、蔗糖、乳糖等糖为受体,以蔗糖作为其优先选择的底物供体,催化转移蔗糖中的果糖基残基到受体的碳链上,促进碳链延伸,从而形成低聚果糖、果聚糖以及低聚乳果糖等产物。
果聚糖蔗糖酶也被用于申请号为CN201610768114.X的中国专利文献,公开了利用肠系膜明串珠菌菌株来源的果聚糖蔗糖酶,以对苯二酚为糖基受体,通过转糖获得熊果苷及熊果苷的寡糖苷。J.Agric.Food Chem.期刊报道《Enzymatic Process YieldingaDiversity of Inulin-Type Microbial Fructooligosaccharides》(DOI:10.1021/acs.jafc.9b03782)公开了以蔗糖作为果糖糖基供体,以芦丁(Inulin)作为糖基受体,形成一系列的低聚果糖糖基化的芦丁衍生物。
为了解决上述技术问题,本发明提供如下技术方案:
一种果糖糖基化的姜黄素制备方法,以果聚糖蔗糖酶为催化剂,以姜黄素为糖基受体,以蔗糖作为糖基化供体进行酶促糖基化反应;
酶催化反应条件为:缓冲液PH 4.5-8.5,终浓度5g/L姜黄素作为糖基受体,终浓度为100g/L蔗糖作为糖基供体,终浓度为10g/L果聚糖蔗糖酶作为催化剂,以终浓度为10g/L槐糖脂作为增溶剂。
优选的,所述缓冲液为pH 4.5-5.5的0.2M柠檬酸乙酸钠缓冲液或pH 6.5-8.5的0.2MPBS缓冲液。
优选的,所述缓冲液pH 6.5-7.5。
优选的,所述果聚糖蔗糖酶通过原核表达系统表达获得,所述果聚糖蔗糖酶的基因序列如SEQ ID NO.1所示。
优选的,一种果糖糖基化的姜黄素,为单果糖糖基化的姜黄素或双果糖糖基化的姜黄素;
所述单果糖糖基化的姜黄素如式Ⅰ所示:
所述双果糖糖基化的姜黄素如式Ⅱ所示:
优选的,一种果糖糖基化的姜黄素在制备抗癌、抗老年痴呆或抗炎药物中的应用。
与现有技术相比,本发明所达到的有益效果是:
(1)、现有技术尚未发现能够使得姜黄素接上糖基化果糖或者果聚糖的果聚糖蔗糖酶。相比于现有技术中已经发现的需要以UDP-葡萄糖作为糖基供体的各类糖基转移酶,果聚糖蔗糖酶的糖基供体为更加廉价易得的蔗糖,这使得采用果聚糖蔗糖酶催化的技术方案相比于现有技术更具有产业化优势及更低的生产成本。
(2)、利用本发明的酶催化反应获得的果糖糖基化的姜黄素,溶解度要远高于对应的葡萄糖糖基化的姜黄素,从而拥有更好的生物利用度。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1果聚糖蔗糖酶的异源表达与纯化。
本实施例所使用的果聚糖蔗糖酶LS来自于密执安棍状杆菌(Clavibactermichiganensis),该酶的核酸及蛋白序列来自于公开的NCBI基因数据库(https://www.ncbi.nlm.nih.gov/),该酶核酸与蛋白序列公众可由参考号(NCBI ReferenceSequence:WP_011931834.1)有NCBI数据库获取。按照大肠杆菌密码偏好性对其进行密码子优化,并在其序列尾部添加6X His tag序列,最终序列如序列1。将密码子优化后的果聚糖蔗糖酶LS基因序列合成并亚克隆至大肠杆菌表达载体pET30a(+)(苏州金唯智公司,pET30a(+)为已公开的商品化大肠杆菌表达载体)。将带有果聚糖蔗糖酶基因的重组质粒pET30a-LS转化大肠杆菌BL21(DE3)宿主,在含有氯霉素(34μg/mL)的LB抗性固体培养基上过夜筛选。选择其中的阳性克隆单菌落分别挑选至摇瓶进行重组酶的表达。重组酶的摇瓶诱导表达采用LB培养基(蛋白胨10g/L、酵母粉5g/L、氯化钠10g/L),将LB抗性固体培养基收集的阳性克隆株接种摇瓶后,在37℃培养至浊度OD600为0.6-1.0后,添加IPTG(异丙基硫代半乳糖苷)的诱导果聚糖蔗糖酶LS的表达(摇瓶内终浓度为0.4mM),同时降温至25℃培养8-14h。之后对不同阳性克隆单菌落诱导发酵所产的发酵液中果聚糖蔗糖酶的酶活进行测定,选择果聚糖蔗糖酶酶活最高(TOP1)的重组菌株作为表达株。
以果聚糖蔗糖酶的酶活检测按照酶活力测定方法将0.5mL 20%(w/v)的蔗糖溶液与0.5mL发酵液在pH 7.0、20mmol/L的磷酸盐缓冲体系下混合均匀,在30℃水浴下反应20min,最后沸水浴煮沸10min终止反应,用高效液相法测定果糖、葡萄糖的生成量,确定酶活。果糖、葡萄糖的生成量最高的重组子为果聚糖蔗糖酶活性最高的表达菌株(TOP1菌株)。
以TOP1菌株作为酶表达生产使用株,使用10L发酵罐培养产酶。发酵罐培养采用发酵培养基(蛋白胨10g/L、酵母粉5g/L、氯化钠8g/L、甘油10g/L、硫酸镁1g/L、磷酸二氢钾1g/L、磷酸氢二钾2g/L),补料为30%甘油,氨水控制pH7.0。接种发酵罐后37℃培养5h开始补料,OD600为20时开始诱导,加入终浓度0.4mM的IPTG并降温至25℃培养,发酵22h放罐。之后,通过低温高速离心(0℃,6000rpm)收集菌体。之后采用PBS缓冲液(pH 7.4,20mM)重悬菌体清洗菌体,之后再次离心(0℃,6000rpm)收集菌体。之后,采用PBS缓冲液(pH 7.4,20mM)重悬菌体通过超声破碎,离心(0℃,6000rpm),收集裂解上清液;采用Ni离子亲和柱柱材对酶进行纯化与分离(Ni Sepharose6Fast Flow,GE Healthcare Bio-Sciences AB),参照NiSepharose 6Fast Flow的产品说明书(Instructions 11-0008-87AF)所建议的步骤对酶进行分离。将所述的4份裂解上清液与1份50%含量的Ni Sepharose 6Fast Flow介质混合,样品和介质室温下置于摇床上低速摇动
孵育1h,之后将将样品和介质加载于PD-10柱上(GE Disposable PD-10,GEHealthcare Bio-SciencesAB),并收集流穿成分。用吸附缓冲液(Binding buffer:20mM磷酸钠,500mM氯化钠,20mM咪唑,pH 7.3)进行清洗,连续收集清洗成分进行280nm波长紫外吸光度检测,约4个柱床体积洗脱后,OD280基本稳定杂蛋白基本洗净。之后用大约5个柱床体积的解析缓冲液(Elutionbuffer:20mM磷酸钠,500mM氯化钠,500mM咪唑,pH 7.3)进行解析洗脱,使得Ni株吸附的果聚糖蔗糖酶解析,收集合并解析洗脱液。将解析洗脱液进行透析脱盐,之后将脱盐后的解析洗脱液冷冻干燥即获得果聚糖蔗糖酶。
实施例2姜黄素的酶促果糖糖基化。
以实施例1所制备的果聚糖蔗糖酶为催化剂,以姜黄素(CAS:458-37-7,纯度98%,鼎瑞化工(上海)有限公司)为糖基受体,以蔗糖作为糖基化供体进行酶促糖基化反应。此外,几个
酶催化反应条件为:以0.2M柠檬酸乙酸钠缓冲液(pH 4.5-5.5)或0.2M PBS(pH6.5-8.5)为催化溶剂体系。反应添加0.5g姜黄素(1.36mmoL)作为糖基受体,10g蔗糖作为糖基供体,1g果聚糖蔗糖酶,另外以1g槐糖脂作为增溶剂,溶解分散于100mL催化溶解体系,并于35℃恒温振荡水浴反应6h。
反应后的催化液中糖基化姜黄素的含量采用HPLC-MS/MS进行分析。色谱分析条件如下:色谱仪:Dinonex Ultimate 3000UHPLC,色谱柱:Eclipse Plus C18100mm×4.6mm,5μm,柱温:30℃,进样量:5.0μL质谱仪:Thermo Scientific Q Exactive,离子源:HESI,翘气速率:40mL/min,辅助气速率:10mL/min,喷雾电压:负离子3.2kV,毛细管温度:320℃,辅助气温度:300℃,S-lens:50%,扫描模式:Fullms/dd-ms2 top10,扫描范围:一级扫描:分辨率70000,范围100~1500m/z;二级扫描:分辨率17500,起始离子50m/z,碰撞电压:NCE30。单果糖糖基化姜黄素,糖基化后的姜黄素相对分子质量MW:530.52,一级质谱529.32mz。而双果糖糖基化姜黄素,其相对分子质量MW:692.66,一级质谱691.32mz。
反应之后生成的糖基化姜黄素的含量结果如表1所列,其表明果聚糖蔗糖酶能够使得姜黄素糖基化。其在pH 6.5-7.5条件下具有较高的糖基化转化率,是一种新的姜黄素糖基化的技术方案。
表.1不同pH条件下果糖糖基化率
反应pH | 单糖基化姜黄素μmol | 双糖基化姜黄素μmol | 合计μmol | 转化率(%) |
4.5 | 166 | 32 | 198 | 14.5 |
5.5 | 235 | 108 | 343 | 25.2 |
6.5 | 598 | 321 | 919 | 67.6 |
7.5 | 584 | 295 | 879 | 64.6 |
8.5 | 103 | 57 | 160 | 11.8 |
单果糖糖基化的姜黄素分子结构为:
双果糖糖基化的姜黄素分子结构为:
实施例3果糖糖基化的姜黄素溶解度
按照实施例2所述果糖糖基化姜黄素样品制备条件的等比例放大后反应所获得的反应液,用于制备果糖糖基化的姜黄素。果糖糖基化的姜黄素采用Isolera快速制备色谱仪进行分离提纯,分离采用SNAP KP-Sil(340g)色谱柱。分离过程为将足量的反应液均匀加入上样杯,后置于真空干燥箱中60℃挥干溶剂,之后将上样杯代替导流器直接安装至SNAP KP-Sil色谱柱上。之后按色谱洗脱条件进行:洗脱流速8mL/min,洗脱流动相为甲醇-0.1%乙酸水溶液的二元混合液,洗脱梯度为0~30min:甲醇15%→30%;30-60min:甲醇30%→50%;60-85min:甲醇50%→75%,紫外检测波长:426nm。按出峰流出时间,依次收集不同峰的馏分。馏分中产物的种类鉴定采取实施实例2中的HPLC-MS/MS进行分析,将不同馏分用HPLC-MS/MS检测器分子量以确定其馏分种类。之后,分别将姜黄素-4’-果糖苷和姜黄素-4,4’-二果糖苷所在馏分溶剂真空旋干,获得分别将姜黄素-4’-果糖苷和姜黄素-4,4’-二果糖苷的固体粉末样品,用于溶解度测试。
不同类型的糖基化的姜黄素的溶解度按照《化合物水溶解度试验GB/T 21845-2008》中的方法进行测试。不同类型糖基化的姜黄素溶解度情况如表2所示。姜黄素在糖基化衍生后其溶解度提高超过两个数量级,同时结果表明,在相同的糖基数量下果糖糖基化的姜黄素的溶解度要远高于对应的葡萄糖糖基化的姜黄素。其预示果糖糖基化的姜黄素可能比现有技术已经发现的葡萄糖基化姜黄素拥有更好的生物利用度。
表2不同类型的姜黄素糖苷的溶解度
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
序列表
<110> 上海龙殷生物科技有限公司
<120> 一种果糖糖基化的姜黄素、制备方法及应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1581
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atgactaaac gtattcgtcg tggcctgtcc gcatctgcag cagctactct ggtagtagct 60
tctgcactgc tggctggtgg ttctgctcaa gctgcaggta ctactccgcc acgtccgacc 120
gtacataccc agaaagccta cgcaccggaa gatgacttca ccgcacactg gacccgcgcg 180
gatgcaaaac agatcgctaa actgtctgac ccgacggttg ctccacgtac caactccatg 240
ccagaagcac tgactatgcc gcaagttccg caggacttcc caaccatgac cgatcaggca 300
tacgtatggg atacctggcc gctgaccgat tcctctggcc agacctatag cgtggacggc 360
tacgacgtga tctttgcact gaccgcgcca cgtactctga gcttcgacga tcgccacacc 420
tatgccaaaa ttggttactt cacccgtcca actggtattc cgtccgaaca gcgtccggaa 480
aacggtggtt ggacctatca aggcaacgtt ttcgaagacg gtgtgaccga cggtatcttc 540
ccggatcaat ccttcacgca gcaggcggaa tggtctggta gcgcacgcat tatggcagac 600
ggcaccgtaa agctgttttt cactgacgta gctttctatc gtgacgcaaa aggtcaagac 660
gttaaaccag ctgacccggt gatctctctg agccagggtc gtgttgaaaa agtggacggc 720
gcggtcgctc tgaaaggctt cgaaactgtt accccgctgc tgcgtcctga tggtcaacgt 780
taccagacta acgaacagaa ctggagcact aacttccgtg acccgttcac tttcactgat 840
ccggaccatc cgggtaagac ctacatggta tttgaagcca acgttgcggg caaacgcggc 900
gaacaagagt gcgacgctac tgacctgggt taccgtaaag gtgacccggc agctgaggac 960
ccgaaagaag tgaccgcacg tggtgcgaac taccagatgg catctatcgg cctggcggtg 1020
gcggatgatg cagatctgac caaatggcac tatctggatc cactgctgga aagcgcatgc 1080
gttaccgacc agactgagcg cccggaagtt atgattgaaa acggtaaaca ctacctgttc 1140
accatcagcc accgtagcac tttcgcggca ggtatcgatg gtccggaagg tgtgtacggc 1200
tttgtcggca acggcctgcg tagcgattac aaaccgatga acggtggttc tggtctggtc 1260
ctgggtaacc cgactaatct gaactacgca ggcggtacgg cttatgcgcc ggactataat 1320
cagaccccgg gtgctttcca agcttattct agctatattc tgccgggcgg cctggtcgag 1380
tcttttatcg acgcggtagg tagcaaagag tctttccgcc gtggtggtac cctgggtccg 1440
actgttaaac tggaattcga tggcgacacc agcgaactgg atcgtggcta cggcgaaggt 1500
ggtctgggtg gttacgcgga cattcctacc actcgcgttt tcgatccggc tcatccacct 1560
cagcaccacc atcatcatca c 1581
Claims (4)
1.一种果糖糖基化的姜黄素制备方法,其特征在于:
以果聚糖蔗糖酶为催化剂,以姜黄素为糖基受体,以蔗糖作为糖基化供体进行酶促糖基化反应;
酶催化反应条件为:缓冲液PH 4.5-8.5,终浓度5g/L姜黄素作为糖基受体,终浓度为100g/L蔗糖作为糖基供体,终浓度为10g/L果聚糖蔗糖酶作为催化剂,以终浓度为10g/L槐糖脂作为增溶剂,35℃恒温振荡水浴反应6h;
所述果聚糖蔗糖酶通过原核表达系统表达获得,所述果聚糖蔗糖酶的基因序列如SEQID NO.1所示;
所述果糖糖基化的姜黄素为单果糖糖基化的姜黄素或双果糖糖基化的姜黄素;
所述单果糖糖基化的姜黄素如式Ⅰ所示:
所述双果糖糖基化的姜黄素如式Ⅱ所示:
2.如权利要求1所述的一种果糖糖基化的姜黄素制备方法,其特征在于,所述缓冲液为pH 4.5-5.5的0.2M柠檬酸乙酸钠缓冲液或pH 6.5-8.5的0.2M PBS缓冲液。
3.如权利要求1所述的一种果糖糖基化的姜黄素制备方法,其特征在于,所述缓冲液pH6.5-7.5。
4.一种果糖糖基化的姜黄素的应用,其特征在于,在制备抗癌、抗老年痴呆或抗炎药物中的应用;
所述果糖糖基化的姜黄素为单果糖糖基化的姜黄素或双果糖糖基化的姜黄素;
所述单果糖糖基化的姜黄素如式Ⅰ所示:
所述双果糖糖基化的姜黄素如式Ⅱ所示:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210301654.2A CN114790472B (zh) | 2022-03-25 | 2022-03-25 | 一种果糖糖基化的姜黄素、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210301654.2A CN114790472B (zh) | 2022-03-25 | 2022-03-25 | 一种果糖糖基化的姜黄素、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114790472A CN114790472A (zh) | 2022-07-26 |
CN114790472B true CN114790472B (zh) | 2024-04-16 |
Family
ID=82462251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210301654.2A Active CN114790472B (zh) | 2022-03-25 | 2022-03-25 | 一种果糖糖基化的姜黄素、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114790472B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958796A (zh) * | 2022-06-26 | 2022-08-30 | 上海龙殷生物科技有限公司 | 一种姜黄素的糖基化方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005312325A (ja) * | 2004-04-27 | 2005-11-10 | Sanei Gen Ffi Inc | 新規糖転移酵素、及びそれを利用したクルクミン配糖体の製造 |
KR20080077913A (ko) * | 2007-02-21 | 2008-08-26 | 전남대학교산학협력단 | 당전이 효소를 이용한 당전이 화합물의 유도체 제조방법 및이로부터 제조된 유도체 |
CN107594205A (zh) * | 2017-10-30 | 2018-01-19 | 农博士(福建)生物技术有限公司 | 肉鸡养殖用饲料、饲料添加剂及其制备方法 |
CN108018269A (zh) * | 2018-01-22 | 2018-05-11 | 江南大学 | 一种热稳定性提高的果聚糖蔗糖酶突变体 |
CN109674054A (zh) * | 2019-01-25 | 2019-04-26 | 龙岩市启明投资有限公司 | 一种水溶性姜黄素低聚糖复合物及其固体饮料的制备方法 |
AU2019264701A1 (en) * | 2018-05-08 | 2020-12-24 | Epc Natural Products Co., Ltd. | Sweetener and flavor compositions, methods of making and methods of use thereof |
CN113207880A (zh) * | 2021-05-28 | 2021-08-06 | 江苏师范大学 | 一种可调表面电荷姜黄素纳米晶体及其制备方法和抗菌应用 |
CN113322219A (zh) * | 2021-02-19 | 2021-08-31 | 南京工业大学 | 一种生物法催化合成姜黄素糖苷类化合物的方法 |
CN113543658A (zh) * | 2018-11-05 | 2021-10-22 | 奇迹生物公司 | 包含鞣花单宁的微生物组合物及使用方法 |
CN113980063A (zh) * | 2021-11-26 | 2022-01-28 | 八叶草健康产业研究院(厦门)有限公司 | 一种六碳糖-姜黄素衍生物的制备方法 |
CN114174489A (zh) * | 2019-08-01 | 2022-03-11 | 阿迈瑞斯公司 | 用于高效生成香兰素的经修饰宿主细胞 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5112859B2 (ja) * | 2004-06-04 | 2013-01-09 | ホリズン サイエンス ピーティーワイ リミテッド | 天然甘味料 |
CN102443027B (zh) * | 2010-10-13 | 2014-10-29 | 南京工业大学 | 果糖基化葛根素及其制备方法与用途 |
ITPD20120021A1 (it) * | 2012-01-26 | 2013-07-27 | Fidia Farmaceutici | "nuove composizioni farmaceutiche contenenti fosfatidilserina e curcumina". |
-
2022
- 2022-03-25 CN CN202210301654.2A patent/CN114790472B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005312325A (ja) * | 2004-04-27 | 2005-11-10 | Sanei Gen Ffi Inc | 新規糖転移酵素、及びそれを利用したクルクミン配糖体の製造 |
KR20080077913A (ko) * | 2007-02-21 | 2008-08-26 | 전남대학교산학협력단 | 당전이 효소를 이용한 당전이 화합물의 유도체 제조방법 및이로부터 제조된 유도체 |
CN107594205A (zh) * | 2017-10-30 | 2018-01-19 | 农博士(福建)生物技术有限公司 | 肉鸡养殖用饲料、饲料添加剂及其制备方法 |
CN108018269A (zh) * | 2018-01-22 | 2018-05-11 | 江南大学 | 一种热稳定性提高的果聚糖蔗糖酶突变体 |
AU2019264701A1 (en) * | 2018-05-08 | 2020-12-24 | Epc Natural Products Co., Ltd. | Sweetener and flavor compositions, methods of making and methods of use thereof |
CN113543658A (zh) * | 2018-11-05 | 2021-10-22 | 奇迹生物公司 | 包含鞣花单宁的微生物组合物及使用方法 |
CN109674054A (zh) * | 2019-01-25 | 2019-04-26 | 龙岩市启明投资有限公司 | 一种水溶性姜黄素低聚糖复合物及其固体饮料的制备方法 |
CN114174489A (zh) * | 2019-08-01 | 2022-03-11 | 阿迈瑞斯公司 | 用于高效生成香兰素的经修饰宿主细胞 |
CN113322219A (zh) * | 2021-02-19 | 2021-08-31 | 南京工业大学 | 一种生物法催化合成姜黄素糖苷类化合物的方法 |
CN113207880A (zh) * | 2021-05-28 | 2021-08-06 | 江苏师范大学 | 一种可调表面电荷姜黄素纳米晶体及其制备方法和抗菌应用 |
CN113980063A (zh) * | 2021-11-26 | 2022-01-28 | 八叶草健康产业研究院(厦门)有限公司 | 一种六碳糖-姜黄素衍生物的制备方法 |
Non-Patent Citations (2)
Title |
---|
Differential effect of biophenols on attenuation of AGE-induced hemoglobin aggregation;Esmat Rahmanifar;《International Journal of Biological Macromolecules》;20200515;第151卷;797-805 * |
微生物转化法制备双脱甲氧基姜黄素糖苷化产物及其对HepG2肿瘤细胞的抑制作用;李锐;《食品与发酵工业》;20160625;第42卷(第06期);20-25 * |
Also Published As
Publication number | Publication date |
---|---|
CN114790472A (zh) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6147370B2 (ja) | ステビオシドからレバウジオシドaを製造する方法 | |
CN111518782B (zh) | 一种糖基转移酶ugtzj1突变体及其应用 | |
JP2010504082A (ja) | 2−O−グリセリル−α−D−グルコピラノシドの生産方法 | |
CN114790472B (zh) | 一种果糖糖基化的姜黄素、制备方法及应用 | |
CN108728422B (zh) | 参与新穿心莲内酯生物合成的糖基转移酶及其编码基因与应用 | |
CN113265434B (zh) | 一种合成udp-半乳糖及合成半乳糖基化合物的方法 | |
CN112708567B (zh) | 一种果糖基转移酶及其高产菌株 | |
CN110699373A (zh) | 尿苷二磷酸葡萄糖高产菌株及其应用 | |
CN108350474B (zh) | 小分子糖基化的方法 | |
CN113322219B (zh) | 一种生物法催化合成姜黄素糖苷类化合物的方法 | |
WO2021131900A1 (ja) | プレニルフラボノイド配糖体、その製造方法及びプレニルフラボノイドの水溶性を向上させる方法 | |
CN113862319A (zh) | 人参糖基转移酶在合成甜菊糖中的应用 | |
CN115418358B (zh) | 一种糖基转移酶及其应用 | |
US20230183766A1 (en) | Bacterial strains and method for producing oligosaccharides | |
US5811539A (en) | Process for isolating and purifying nucleotide-activated sugars from biological sources | |
CN109097423B (zh) | 应用交替糖蔗糖酶催化合成单、二葡萄糖基莱鲍迪苷a | |
CN111876447B (zh) | 一种生产迷迭香酸的菌株及方法 | |
EP2186904B1 (en) | Method for producing glucose derivatives | |
CN111635894B (zh) | 粉蝶霉素糖基转移酶sGT1及应用 | |
CN115478060B (zh) | 一种糖基转移酶及其应用 | |
CN115725528B (zh) | 一种糖基转移酶及其应用 | |
Zhou et al. | Isolation and characterization of a novel α-glucosidase with transglycosylation activity from Arthrobacter sp. DL001 | |
CN113584066A (zh) | 一种γ-环糊精葡萄糖基转移酶构建方法及应用 | |
CN117247917A (zh) | 一种麦芽糖磷酸化酶突变体h416c及其糖基化修饰酪醇的应用 | |
CN117737029A (zh) | 一种糖基转移酶突变体及其在络塞合成中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |